About the study

A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

1. HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine
2. or platinum-containing chemotherapy (2nd-line or 3rd-line)
3. Adequate Bone Marrow Function.
4. Adequate Renal & Liver Function.
5. Adequate Performance Status

Exclusion criteria

1. Patients with known symptomatic CNS metastases or leptomeningeal disease requiring steroids.
2. Prior treatment with any anti-CD47 or anti-SIRPα agent.
3. Prior treatment with ramucirumab.

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.